



AgiOS to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016

August 5, 2016

CAMBRIDGE, Mass., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios Pharmaceuticals

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Contact:

Renee Leck, Senior Manager, Investor & Public Relations

Renee.Leck@agios.com

617-649-8299



Agios Pharmaceuticals